Oxford Biomedica PLC Notice of Interim Results (9536L)
25 July 2017 - 4:01PM
UK Regulatory
TIDMOXB
RNS Number : 9536L
Oxford Biomedica PLC
25 July 2017
Oxford BioMedica: Notice of Interim Results
Results date: 17 August 2017
Oxford, UK - 25 July 2017: Oxford BioMedica plc (LSE: OXB)
("OXB" or "the Group"), a leading gene and cell therapy group, will
be announcing its interim results for the six months ended 30 June
2017 on Thursday 17 August 2017.
A briefing for analysts will be held at 09:30 GMT on 17 August
2017 at 1 Cornhill, London, EC3V 3ND. There will be a simultaneous
live conference call with Q&A and the presentation will be
available on the Group's website at www.oxfordbiomedica.co.uk. An
audio replay file will be made available shortly afterwards.
Please contact Consilium Strategic Communications for further
details.
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865 783 000
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Financial PR Enquiries: Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal / Philippa Gardner / Laura
Thornton
Consilium Strategic Communications
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, Orchard
Therapeutics and Immune Design, through which it has long-term
economic interests in other potential gene and cell therapy
products. Oxford BioMedica is based across several locations in
Oxfordshire, UK and employs more than 250 people. Further
information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORFZLLLDDFEBBZ
(END) Dow Jones Newswires
July 25, 2017 02:01 ET (06:01 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024